<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1406">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01766024</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-033-1</org_study_id>
    <nct_id>NCT01766024</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Pharmacodynamics Study of BCD-033 Compared to Rebif® in Healthy Volunteers</brief_title>
  <official_title>International Multicenter Randomized Double-blind Crossover Study of Pharmacokinetics, Pharmacodynamics and Tolerability of BCD-033 (CJSC BIOCAD, Russia) and Rebif® (Merck Serono S.p.А., Italy) After Single Subcutaneous Administration to Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <authority>Russian Federation: Ministry of Health of the Russian Federation</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized double-blind crossover study of pharmacokinetics, pharmacodynamics and
      tolerability of BCD-033 (interferon beta-1a manufactured by CJSC BIOCAD, Russia) and Rebif®
      (Merck Serono S.p.A.., Italy) in healthy volunteers. The purpose of the study is to
      demonstrate the non-inferiority of pharmacokinetics, pharmacodynamics and tolerability
      parameters after single subcutaneous injection. Each dtug will be administered to each
      volunteer at a dose of 44 µg as a single subcutaneous injection with an interval of at least
      14 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each dtug (BCD-033 and Rebif) will be administered to each volunteer at a dose of 44 µg as a
      single subcutaneous injection with an interval of at least 14 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Area Under Concentration-time Curve (AUC) of Interferon (IFN) Beta-1a From the Moment of Drug Administration Until 48 Hours and to Infinity(AUC(0-48) and AUC(0-∞) Respectively)</measure>
    <time_frame>up to 48 h</time_frame>
    <safety_issue>No</safety_issue>
    <description>Primary outcome measure for pharmacokinetics analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Interferon Beta-1a</measure>
    <time_frame>up to 48 h</time_frame>
    <safety_issue>No</safety_issue>
    <description>Primary outcome measure for pharmacokinetics analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-168) and AUC(0-∞) of Neopterin and MxA Protein</measure>
    <time_frame>up to 168 h</time_frame>
    <safety_issue>No</safety_issue>
    <description>Primary outcome measure for pharmacodynamics analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Тmax of Interferon Beta-1a</measure>
    <time_frame>up to 48 h</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcome measure for pharmacokinetics analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Т½ of Interferon Beta-1a</measure>
    <time_frame>up to 48 h</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcome measure for pharmacokinetics analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Кel of Interferon Beta-1a</measure>
    <time_frame>up to 48 h</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcome measure for pharmacokinetics analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cl of Interferon Beta-1a</measure>
    <time_frame>up to 48 h</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcome measure for pharmacokinetics analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Neopterin and MxA Protein</measure>
    <time_frame>up to 168 h</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcome measure for pharmacodynamics analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Neopterin and MxA Protein</measure>
    <time_frame>up to 168 h</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcome measure for pharmacodynamics analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event (AE) and Serious Adverse Event (SAE) Incidence</measure>
    <time_frame>up to Day 43</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Secondary outcome measure for safety assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE of Garde 3-4 Incidence</measure>
    <time_frame>up to Day 43</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Secondary outcome measure for safety assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local Reaction Incidence</measure>
    <time_frame>up to Day 43</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Secondary outcome measure for tolerability assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Withdrawal Rate Due to AE</measure>
    <time_frame>up to Day 43</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Secondary outcome measure for safety assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BCD-033 → Rebif</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers in this group initially will receive a single sc injection of the study drug BCD-033 (interferon beta-1a) at a dose of 44 µg (on Day 1) and then, after at least 14 days, a single sc injection of the reference drug Rebif® (interferon beta-1a) at a dose of 44 µg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rebif → BCD-033</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers in this group initially will receive a single sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg (on Day 1) and then, after at least 14 days, a single sc injection of the study drug BCD-033 (interferon beta-1a) at a dose of 44 µg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon beta-1a</intervention_name>
    <description>Each volunteer will receive 1 subcutaneous (sc) injection of the study drug BCD-033 (interferon beta-1a) and 1 sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg with an interval of at least 14 days.</description>
    <arm_group_label>BCD-033 → Rebif</arm_group_label>
    <arm_group_label>Rebif → BCD-033</arm_group_label>
    <other_name>BCD-033</other_name>
    <other_name>Rebif</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent;

          -  Male gender;

          -  Age 18 - 45 years inclusive;

          -  Body mass index (BMI) (18,5 - 24,99 kg/m2);

          -  Healthy condition proven by the volunteer's history, global assessment and laboratory
             analysis results:

          -  Absence in past medical history and at screening of clinically significant
             dysfunctions of circulatory, respiratory, nervous, hematopoietic, endocrine and
             digestive systems, liver and kidneys;

          -  Haematology and biochemistry tests, urinalysis and thyroid hormone analysis results
             are within normal limits according to standards of the study site. Screening
             laboratory analyses should be performed not more than 14 days before volunteer's
             inclusion in the study;

          -  Hemodynamic parameters are within normal limits: systolic blood pressure - from 100
             to 139 mmHg, diastolic blood pressure - from 60 to 90 mmHg, heart rate - from 50 to
             90 bpm;

          -  Absence of history of chronic infection (tuberculosis) and chronic inflammation;

          -  Absence of HIV, hepatitis B and C virus, syphilis;

          -  Absence of acute infections within 4 weeks before inclusion in the study;

          -  Absence of psychiatric disorders and other conditions that can interfere with
             volunteer's ability to follow the study protocol, including depression;

          -  Well-being (in volunteer's opinion) within 30 days before participation in the study;

          -  Absence of history of systematic alcohol and drug abuse;

          -  Ability of the volunteer, in investigator's opinion, to follow the study protocol
             procedures and requirements;

          -  Willingness of volunteers and their sexual partners of childbearing potential to use
             reliable contraception methods starting from 2 weeks before inclusion into the study
             and until 4 weeks after receiving the last dose of the investigational products. This
             criterion is not applicable to patients who underwent surgical sterilization.
             Reliable contraceptive measures include one barrier method in combination with one of
             the following methods: spermicides, intrauterine device or oral contraceptives used
             by participant's partner;

          -  Consent to avoid alcohol intake within 24 hours before and 8 days after each
             administration of the test or reference drugs;

          -  Consent to avoid grapefruit juice (or other products containing grapefruit) intake
             within 72 hours before and 8 days after each administration of the study or reference
             drugs.

        Exclusion Criteria:

          -  Previous use of IFN-β1-containing medications at any time before inclusion;

          -  History of serious allergic reactions (anaphylaxis or multiple allergy);

          -  Known allergy or intolerance to interferons or any other components of study or
             reference drugs;

          -  Major surgery within 30 days before screening;

          -  Impossibility to install venous catheter for blood sampling (e.g. because of skin
             disorders at the sites of venipuncture);

          -  Diseases or other conditions that can interfere with the investigational drugs
             pharmacokinetics (e.g. chronic liver, kidney, blood, circulatory system, lung or
             neuroendocrine diseases, including diabetes mellitus and others);

          -  History of epileptic seizures;

          -  Regular oral or parenteral use of any medications including over-the-counter drugs,
             vitamins and nutritional additives within less than 2 weeks before inclusion in the
             study;

          -  Intake of medications, including over-the-counter drugs and biologically active
             additives that can influence hemodynamics, liver function etc. (barbiturates,
             omeprazole, cimetidine etc.) within less than 30 days before inclusion in the study;

          -  Intake of medications that influence immune status (cytokines and their inductors,
             glucocorticoids etc.) within less than 30 days before participation in the study;

          -  Smoking more than 10 cigarettes per day;

          -  Subjects who consume more than 10 units of alcohol per week or who have history of
             alcohol abuse or evidence of drug/chemical abuse (one unit of alcohol equals ½ l [500
             ml] of beer, one glass [200 ml] of wine or l shot glass [50 ml] of spirits);

          -  Donation of 450 ml and more of blood or plasma within 2 months before inclusion in
             the study;

          -  Participation in other clinical studies within less than 1 month before inclusion in
             the study or simultaneous participation in another clinical study;

          -  Previous participation in this study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivan Sardaryan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>City Mariin Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City Mariin Hospital</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194104</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://www.biocad.ru</url>
  </link>
  <verification_date>February 2015</verification_date>
  <lastchanged_date>February 2, 2015</lastchanged_date>
  <firstreceived_date>January 10, 2013</firstreceived_date>
  <firstreceived_results_date>February 2, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>interferon beta-1a</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>volunteers</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon beta 1a</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BCD-033 → Rebif</title>
          <description>Volunteers in this group initially will receive a single sc injection of the study drug BCD-033 (interferon beta-1a) at a dose of 44 µg (on Day 1) and then, after at least 14 days, a single sc injection of the reference drug Rebif® (interferon beta-1a) at a dose of 44 µg.
Interferon beta-1a: Each volunteer will receive 1 subcutaneous (sc) injection of the study drug BCD-033 (interferon beta-1a) and 1 sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg with an interval of at least 14 days.</description>
        </group>
        <group group_id="P2">
          <title>Rebif → BCD-033</title>
          <description>Volunteers in this group initially will receive a single sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg (on Day 1) and then, after at least 14 days, a single sc injection of the study drug BCD-033 (interferon beta-1a) at a dose of 44 µg.
Interferon beta-1a: Each volunteer will receive 1 subcutaneous (sc) injection of the study drug BCD-033 (interferon beta-1a) and 1 sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg with an interval of at least 14 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BCD-033 → Rebif</title>
          <description>Volunteers in this group initially will receive a single sc injection of the study drug BCD-033 (interferon beta-1a) at a dose of 44 µg (on Day 1) and then, after at least 14 days, a single sc injection of the reference drug Rebif® (interferon beta-1a) at a dose of 44 µg.
Interferon beta-1a: Each volunteer will receive 1 subcutaneous (sc) injection of the study drug BCD-033 (interferon beta-1a) and 1 sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg with an interval of at least 14 days.</description>
        </group>
        <group group_id="B2">
          <title>Rebif → BCD-033</title>
          <description>Volunteers in this group initially will receive a single sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg (on Day 1) and then, after at least 14 days, a single sc injection of the study drug BCD-033 (interferon beta-1a) at a dose of 44 µg.
Interferon beta-1a: Each volunteer will receive 1 subcutaneous (sc) injection of the study drug BCD-033 (interferon beta-1a) and 1 sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg with an interval of at least 14 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="32"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="32"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="32"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="32"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="32"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Russian Federation</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="32"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under Concentration-time Curve (AUC) of Interferon (IFN) Beta-1a From the Moment of Drug Administration Until 48 Hours and to Infinity(AUC(0-48) and AUC(0-∞) Respectively)</title>
        <description>Primary outcome measure for pharmacokinetics analysis</description>
        <time_frame>up to 48 h</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>BCD-033</title>
            <description>the endpoint was assessed in all the volunteer who received BCD-033</description>
          </group>
          <group group_id="O2">
            <title>Rebif</title>
            <description>the endpoint was assessed in all the volunteer who received Rebif</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Area Under Concentration-time Curve (AUC) of Interferon (IFN) Beta-1a From the Moment of Drug Administration Until 48 Hours and to Infinity(AUC(0-48) and AUC(0-∞) Respectively)</title>
            <description>Primary outcome measure for pharmacokinetics analysis</description>
            <units>(pg/ml)•h</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6318.3" lower_limit="5368.4" upper_limit="7484.9"/>
                  <measurement group_id="O2" value="6807.9" lower_limit="5714.9" upper_limit="8920.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Interferon Beta-1a</title>
        <description>Primary outcome measure for pharmacokinetics analysis</description>
        <time_frame>up to 48 h</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>BCD-033</title>
            <description>the endpoint was assessed in all the volunteer who received BCD-033 (interferon beta-1a)</description>
          </group>
          <group group_id="O2">
            <title>Rebif</title>
            <description>the endpoint was assessed in all the volunteer who received Rebif (interferon beta-1a) a</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cmax of Interferon Beta-1a</title>
            <description>Primary outcome measure for pharmacokinetics analysis</description>
            <units>pg/ml</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="104.9" lower_limit="80.2" upper_limit="123.4"/>
                  <measurement group_id="O2" value="102.4" lower_limit="83.6" upper_limit="148.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-168) and AUC(0-∞) of Neopterin and MxA Protein</title>
        <description>Primary outcome measure for pharmacodynamics analysis</description>
        <time_frame>up to 168 h</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>BCD-033</title>
            <description>the endpoint was assessed in all the volunteer who received BCD-033</description>
          </group>
          <group group_id="O2">
            <title>Rebif</title>
            <description>the endpoint was assessed in all the volunteer who received Rebif</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="32"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>AUC(0-168) and AUC(0-∞) of Neopterin and MxA Protein</title>
            <description>Primary outcome measure for pharmacodynamics analysis</description>
            <units>(ng/ml)*h</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>neopterin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="552.7" lower_limit="458.1" upper_limit="661.6"/>
                  <measurement group_id="O2" value="537.6" lower_limit="392.6" upper_limit="680.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MxA protein</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2444.2" lower_limit="2005.5" upper_limit="3011.2"/>
                  <measurement group_id="O2" value="2131.2" lower_limit="1728.0" upper_limit="3245.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Тmax of Interferon Beta-1a</title>
        <description>Secondary outcome measure for pharmacokinetics analysis</description>
        <time_frame>up to 48 h</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Т½ of Interferon Beta-1a</title>
        <description>Secondary outcome measure for pharmacokinetics analysis</description>
        <time_frame>up to 48 h</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Кel of Interferon Beta-1a</title>
        <description>Secondary outcome measure for pharmacokinetics analysis</description>
        <time_frame>up to 48 h</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cl of Interferon Beta-1a</title>
        <description>Secondary outcome measure for pharmacokinetics analysis</description>
        <time_frame>up to 48 h</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of Neopterin and MxA Protein</title>
        <description>Secondary outcome measure for pharmacodynamics analysis</description>
        <time_frame>up to 168 h</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax of Neopterin and MxA Protein</title>
        <description>Secondary outcome measure for pharmacodynamics analysis</description>
        <time_frame>up to 168 h</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Event (AE) and Serious Adverse Event (SAE) Incidence</title>
        <description>Secondary outcome measure for safety assessment</description>
        <time_frame>up to Day 43</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AE of Garde 3-4 Incidence</title>
        <description>Secondary outcome measure for safety assessment</description>
        <time_frame>up to Day 43</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Local Reaction Incidence</title>
        <description>Secondary outcome measure for tolerability assessment</description>
        <time_frame>up to Day 43</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Withdrawal Rate Due to AE</title>
        <description>Secondary outcome measure for safety assessment</description>
        <time_frame>up to Day 43</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>BCD-033</title>
          <description>the endpoint was assessed in all the volunteer who received BCD-033</description>
        </group>
        <group group_id="E2">
          <title>Rebif</title>
          <description>the endpoint was assessed in all the volunteer who received Rebif</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu-like syndrom</sub_title>
                <description>Fever, aches, chills, headache, weakness</description>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="32"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Local reactions</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="32"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Trials</name_or_title>
      <organization>BIOCAD</organization>
      <phone>7 (812) 380 49 33 ext 925</phone>
      <email>biryulin@biocad.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
